| Trial ID: | L3109 |
| Source ID: | NCT04572165
|
| Associated Drug: |
Ozempic®
|
| Title: |
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
|
| Acronym: |
|
| Status: |
ENROLLING_BY_INVITATION
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Ozempic®|DRUG: Active Comparator|DRUG: Rybelsus®
|
| Outcome Measures: |
Primary: Occurrence of first time malignant neoplasm of pancreas, Incidence, From when semaglutide entered the market in Denmark, Sweden, and Norway (Q3/Q4 2018) until December 31, 2023 |
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S | Collaborators: Department of Public Health, University of Southern Denmark
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
6e+05
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2021-01-26
|
| Completion Date: |
2024-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-01-02
|
| Locations: |
Novo Nordisk Investigational Site, Odense, 5000, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT04572165
|
